CSL Ltd. has signed an agreement to acquire Talecris Biotherapeutics Holdings Corp. for $3.1 billion, enhancing its position in the global plasma market. Talecris produces plasma medicines in the U.S. and operates 56 plasma collection centers and two manufacturing facilities. For the year ended June 30, Talecris had sales of $1.2 billion and earnings of $258 million. The company also operates a sterile CMO business.     CSL managing director Brian McNamee commented, “Talecris is highly ...